Infinity Pharmaceuticals Inc. (INFI) Reports First Quarter 2013 Financial Results and Provides Company Update
5/8/2013 7:41:54 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) reported its first quarter 2013 financial results and ongoing progress with IPI-145, its potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, and retaspimycin HCl, its potent and selective inhibitor of heat shock protein 90 (Hsp90).
Help employers find you! Check out all the jobs and post your resume.